アブストラクト
| Title | 3. 骨粗鬆症と鑑別すべき疾患 : FGF23関連低リン血症性くる病・骨軟化症 |
|---|---|
| Subtitle | 特集 : 骨粗鬆症診療 update - 最新の診断と治療 - VI. 特論 |
| Authors | 伊東伸朗 |
| Authors (kana) | |
| Organization | 東京大学医学部附属病院 腎臓・内分泌内科 |
| Journal | 日本臨牀 |
| Volume | 78 |
| Number | 12 |
| Page | 2162-2173 |
| Year/Month | 2020 / 12 |
| Article | 報告 |
| Publisher | 日本臨牀社 |
| Abstract | 「はじめに」Fibroblast growth factor 23 (FGF23) は骨細胞で作られるリン濃度調節ホルモンである. FGF23が不適切に分泌され, 慢性低リン血症性くる病・骨軟化症を生じる病態を, 総じてFGF23関連低リン血症性くる病・骨軟化症 (FGF23-related hypophosphatemic rickets / osteomalacia : FGF23rHR) と呼んでいる. 先天性FGF23rHRではX染色体連鎖性低リン血症性くる病・骨軟化症 (X-linked hypophosphatemic rickets / osteomalacia : XLH) , 後天性FGF23rHRではFGF23産生腫瘍による腫瘍性骨軟化症 (tumor-induced osteomalacia : TIO) の頻度が高い. |
| Practice | 医学総合 |
| Keywords | FGF23, rickets, osteomalacia, tumor-induced osteomalacia, X-linked hypophosphatemic rickets / osteomalacia |
- 全文ダウンロード： 従量制、基本料金制の方共に1,243円(税込) です。
参考文献
- 1) Fukumoto S, Yamashita T: FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23. Bone 40: 1190-1195, 2007.
- 2) Carpenter TO, et al: A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 26: 1381-1388, 2011.
- 3) Takashi Y, et al: Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proc Natl Acad Sci USA 116: 11418-11427, 2019.
- 4) Shimada T, et al: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004.
- 5) Martin A, et al: Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 25: 2551-2562, 2011.
残りの18件を表示する
- 6) Lee JC, et al: Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29: 1335-1346, 2016.
- 7) Shimizu Y, et al: Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 45: 814-816, 2009.
- 8) Chesher D, et al: Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41: 865-876, 2018.
- 9) Nakamura I, et al: Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet 104: 492-497, 1999.
- 10) Karaplis AC, et al: Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice. Endocrinology 153: 5906-5917, 2012.
- 11) Fukumoto S, et al: Pathogenesis and diagnostic criteria for rickets and osteomalacia-proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society. J Bone Miner Metab 33: 467-473, 2015.
- 12) 公益財団法人 かずさDNA研究所 ウェブサイト[https://www.kazusa.or.jp/genetest/test_non_insured.html]
- 13) Feng J, et al: The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J 64: 675-683, 2017.
- 14) Endo I, et al: Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62: 811-816, 2015.
- 15) Verge CF, et al: Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325: 1843-1848, 1991.
- 16) DeLacey S, et al: Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone 127: 386-392, 2019.
- 17) Imel EA, et al: Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393: 2416-2427, 2019.
- 18) Portale AA, et al: Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int 105: 271-284, 2019.
- 19) Folpe AL, et al: Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28: 1-30, 2004.
- 20) Nguyen BD, Wang EA: Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med 24: 130-131, 1999.
- 21) Ito N, et al: Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med 268: 390-394, 2010.
- 22) Clifton-Bligh RJ, et al: Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab 98: 687-694, 2013.
- 23) Bergwitz C, et al: Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia. N Engl J Med 365: 1625-1635, 2011.
